News

Category:
|
September 29, 2020

Dewpoint Therapeutics Series B $77M raise gains significant media attention

The announcement of Dewpoint Therapeutics successful $77 million Series B raise has received significant attention in from both Industry and main-stream media. A selection of key coverage and analysis can be found via the links below.

Read more on bostonglobe.com

Read more on endpts.com

Read more on fiercebiotech.com

Media Contact

Jeanette Bressi
VP, Head of Communications & PR
Dewpoint Therapeutics
+1 609-439-3997 | jbressi@dewpointx.com

Investor Contact

Scott Peterson, Ph.D.
SVP, Corporate Development and Investor Relations
Dewpoint Therapeutics
speterson@dewpointx.com
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2023 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science